Clinical Trial: An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barre Syndrome (FORWARD Study)

U.S., June 14 -- ClinicalTrials.gov registry received information related to the study (NCT07020819) titled 'An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barre Syndrome (FORWARD Study)' on June 06.

Brief Summary: The goal of this open label study is to measure pharmacokinetics, pharmacodynamics, early efficacy, and safety of tanruprubart in adult and pediatric participants, in the United States, Canada, and Europe.

Study Start Date: June, 2025

Study Type: INTERVENTIONAL

Condition: Guillain-Barre Syndrome

Intervention: DRUG: Tanruprubart

Solution for IV infusion.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Annexon, Inc.

Published by HT Digital Content Servi...